Professeur Émérite

Sorbonne Université
4 Place Jussieu, 75252 Paris cedex 5
Couloir 33-43 4ème étage
Tel: 33(0)1 44 27 95 55

Also staff member of Ecole Nationale Supérieure de Chimie de Paris (ENSCP-Chimie-ParisTech)
http://scholar.google.fr (citations : >14549)

Parcours Scientifique

  • 1969, Ph.D. in Organic Chemistry, University of Rennes, France (1969), Supervisor R. Dabard.
  • 1973, State Doctorate in Physical Sciences, University of Rennes, France.
  • 1970-76 : Chargé de Recherche CNRS
  • Oct 1973-Sept. 1974 : Research Associate, University Chemical Laboratory with The Lord (Jack) Lewis of Newnham , Cambridge ( European Grant)
  • 1976-1982 : Director of Research CNRS
  • May-Dec 1981 : Associate Professor, Mc Master University
  • April 1981, July 1984, 86, 87, 88, 89, 91 : Visiting Scientist, McGill University
  • May 1999 : Invited Professor, Zurich
  • 2001,2002,2003,2004,2009,2010 (9 months altogether) : von Humboldt Awardee ,LMU, Munich
  • Since 1982 : Professor, Ecole Nationale Supérieure de Chimie de Paris
  • 1984-2009 : Director of a mixed Laboratory CNRS-ENSCP
  • 2010 -2013 : Director of the bioorganometallic chemistry team in the Charles Friedel Department
  • since 2014:member of the chemical biology team at the IPCM
  • 2014 Founder at PSL of the first start–up company:Feroscan devoted to unprecedented antitumor species


  • 1975 Prize from the French Chemical Society, Organic Chemistry Division
  • 1996 Prize from the “Académie des Sciences” (Jean Reynaud Prize)
  • 1997 Elected by an international Committee to the “Institut Universitaire de France” (chair of bioorganometallic chemistry)
  • 2001 Gay-Lussac von Humboldt Award for Munich and Gottingen
  • 2002 Pioneer Award (Amer. Inst. Chem.) (Boston)
  • 2003 RCS Centenary Medal (U.K.)
  • 2003 J.T. Donald Lecturer, Mc Gill University
  • 2004 Elsevier Bioorganometallic Chemistry Award (Zurich)
  • 2005 Wheeler Lecturer, University College Dublin
  • 2006 “Chevalier dans l’ordre de la Légion d’Honneur” (promoted by the Minister of Research and Universities)
  • 2009 Special issue of J. Organomet. Chem. (694, March 15) dedicated to G. Jaouen and highlighting the founding role played by him for the birth of the field. See also Chem. Soc. Rev., 2009, 38, 391-401 (list of the ten key dates in transition metal organometallic chemistry)
  • 2011 “Future directions in organometallic chemistry”, Organometallics, 2011, 30, 20-27. Invited review ,classified as highly cited paper in 2014 by Reuters
  • 2012 Fellow of EURACS ,European Academy of Sciences ( Belgium) ,Socio of the “Istituto Lombardo Accademia di Scienze e Lettere”(Milan) and member of the Academia Europaea ( London)
  • 2013 ParisTech Award (Consortium of the leading technological schools in Paris)


The principal contributions of Gérard Jaouen to the development of bioorganometallic chemistry whose potential he first foresaw are :

  • A new type of FT-IR-based bioassay, named CMIA (Carbonyl Metallo ImmunoAssay), the principle of which has now been adopted for IR imaging in Asia (Singapore, Hong Kong) and in Europe
  • The development of an unprecedented multi-immunoassay based on CMIA
  • The synthesis of organometallic suicide substrates for use in studies of the active sites of hormone receptors
  • Access to radiopharmaceuticals with very high affinity for the target receptor
  • The concept of “ferrocifens” with double functionality against hormone-independent breast cancers
  • The area of artificial organometallic enzymes, “OMzymes”, the first alderases
  • The intra cancer cell selective activation of polyphenols into mild quinone methides thanks to an innovating organometallic redox antenna, changing the paradigm for metallodrugs (senescence, apoptosis, bioavailability, unique mechanisms via a kronatropic effect, and first in vivo results on glioma and epithelial ovarian cancers included)
  • The identification of specific redox proteins overexpressed in cancer cells and targeted by ferrocifen cytostatic derivatives in order to trigger senescence for these cells when apoptosis is not operating (so far incurable tumors).This mitochondrial approach inducing a senescence trail can circumvent cancer cells resistant to pro-apoptotic stimuli

Choix de Publications

  1. Jaouen, G. ; Vessieres, A. ; Top, S. ; Ferrocifen Type Anticancer Drugs ; Chem. Soc. Rev. 2015, 44, 8802.
  2. Wang, Y. ; Dansette, P. M. ; Pigeon, P. ;Top, S. ; McGlinchey, M. J. ; Mansuy, D. ; Jaouen, G. ; 
    A New Generation of Ferrociphenols Leads to a Great Diversity of Reactive Metabolites, and Exhibits Remakable Antiproliferative Properties ; Chem. Sc. 2018, 9, 70-78.
  3. Wang,Y., Pigeon, P. ; Top, S. ; McGlinchey, M. J. ; Jaouen, G. ; Organometallic Antitumor Compounds : Ferrocifens as Precursors to Quinone Methides ; Angew. Chem. Int. Ed. 2015, 54, 10230.
  4. Wang,Y. ; Richard, M.-A. ; Top, S. ; Dansette, P. M. ; Pigeon, P. ; Vessieres, A. ; Mansuy, D. ; Jaouen, G. ; Ferrocenyl Quinone Methide-Thiol Adducts as New Antiproliferative Agents : Synthesis, Metabolic Formation from Ferrociphenols, and Oxidative Transformation ; Angew. Chem. Int. Ed.2016, 55, 10431.
  5. Hillard, E. A. ;Jaouen, G. ; Bioorganometallics :Future Trends in Drug Discovery, Analytical Chemistry , and Catalysis ; Organometallics 2011, 30, 20-27.